{"doi":"10.1002/ana.27268","title":"Intravenous Glyburide in Medical and Endovascular‐Treated Large‐Core Stroke: A Subgroup Analysis of the <scp>CHARM</scp> Randomized Clinical Trial","abstract":"OBJECTIVE: The Glibenclamide for Large Hemispheric Infarction Analyzing mRS and Mortality (CHARM) trial enrolled participants with large hemispheric infarction, randomized to a placebo or intravenous glyburide. Our objective in this post-hoc study was to evaluate the relationship between baseline stroke volume and the potential efficacy of i.v. glyburide. METHODS: Participants enrolled in CHARM and aged ≤70 years were included if a <125 ml ischemic core lesion volume was measured by computed tomography perfusion or diffusion magnetic resonance imaging. The primary endpoint was a shift analysis on the 90-day modified Rankin Scale. Independent variables included age, sex, baseline National Institutes of Health Stroke Scale, world region, tissue plasminogen activator, and endovascular thrombectomy. RESULTS: A total of 147 participants with a baseline large-core stroke volume <125 ml were available for this analysis (mean age 58 years, 37% women, baseline National Institutes of Health Stroke Scale 18, and the time to study drug was 9.1 ± 2.1 h). The median baseline core volume of 92 mL (IQR 81-107 ml) did not differ by treatment arm. The i.v. glyburide-treated participants had a favorable shift in outcome relative to the placebo (adjusted common odds ratio 2.11, 95% CI 1.10-4.01, p = 0.02). In patients who underwent endovascular thrombectomy, i.v. glyburide-treated subjects had a favorable outcome (adjusted common odds ratio 8.19, 95% CI 1.60-42.0, p = 0.01), fewer decompressive craniectomies (0% vs 25%, P = 0.02), less midline shift (4.2 ± 2.5 mm vs 7.6 ± 5.5 mm, p = 0.02), and lower 90-day mortality (5.6% vs 31%, p = 0.05) compared with the placebo, respectively. INTERPRETATION: This post-hoc analysis of the CHARM trial provides hypothesis-generating evidence that i.v. glyburide may improve outcome in large-core stroke <125 ml, especially among endovascular thrombectomy-treated patients. These results require confirmation in a prospective randomized clinical trial. ANN NEUROL 2025;98:616-624.","journal":"Annals of Neurology","year":2025,"id":530768,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7338,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":58030,"name":"Jeffrey L. Saver","orcid":"0000-0001-9141-2251","position":1,"is_corresponding":false},{"id":249917,"name":"Bruce Campbell","orcid":"0000-0003-3632-9433","position":2,"is_corresponding":false},{"id":252224,"name":"Gregory W. Albers","orcid":"0000-0003-0263-4632","position":3,"is_corresponding":false},{"id":272175,"name":"Bradley J. Molyneaux","orcid":"0000-0002-3377-1229","position":4,"is_corresponding":false},{"id":654799,"name":"Holly E. Hinson","orcid":"0000-0003-1598-9782","position":5,"is_corresponding":false},{"id":1206000,"name":"Marcelo Borges Rocha","orcid":"0000-0003-4472-7423","position":6,"is_corresponding":false},{"id":1410711,"name":"Shilpi Mittal","orcid":"0000-0001-8482-0599","position":7,"is_corresponding":false},{"id":1126204,"name":"Stephen Bacchi","orcid":"0000-0001-5130-8628","position":8,"is_corresponding":false},{"id":855108,"name":"Gagan Sharma","orcid":"0009-0009-3427-0897","position":9,"is_corresponding":false},{"id":249219,"name":"Charlotte Cordonnier","orcid":"0000-0002-5697-6892","position":10,"is_corresponding":false},{"id":301023,"name":"Thorsten Steiner","orcid":"0000-0002-5080-8222","position":11,"is_corresponding":false},{"id":249944,"name":"Ḱazunori Toyoda","orcid":"0000-0002-8346-9845","position":12,"is_corresponding":false},{"id":58042,"name":"Max Wintermark","orcid":"0000-0002-6726-3951","position":13,"is_corresponding":false},{"id":436230,"name":"Raul G. Nogueira","orcid":"0000-0003-4532-153X","position":14,"is_corresponding":false},{"id":1411136,"name":"Sven Jacobson","orcid":null,"position":15,"is_corresponding":false},{"id":240758,"name":"J. Marc Simard","orcid":"0000-0002-5373-1988","position":16,"is_corresponding":false},{"id":256547,"name":"Kevin N. Sheth","orcid":"0000-0003-2003-5473","position":17,"is_corresponding":false},{"id":350022,"name":"W. Taylor Kimberly","orcid":"0000-0002-2519-8530","position":0,"is_corresponding":true}],"reference_count":26,"raw_metadata":null,"created_at":"2026-07-19T02:51:10.077559Z","pmid":"40476628","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}